作为治疗选择在一个16岁的EVALI的plasmapheresis:一个案例报告
Christine Gaik1, Christian Arndt, Nadine Mand
1From the Department of Anesthesiology and Intensive Care Medicine, University Hospital Giessen and Marburg, Campus Marburg, Philipps-University Marburg, Germany (CG, CA, HW), Neonatology and Pediatric Intensive Care Medicine, Department of Pediatrics, Philipps-University, Marburg, Germany (NM), Paediatric Pulmonology, Department of Pediatrics, Philipps-University, Marburg, Germany (MB), Clinic for Paediatric Pneumology, Allergology and Neonatology, Hannover Medical School, German Centre for Lung Research, Hannover, Germany (NS), Institute of Pathology, Philipps-University Marburg and University Hospital Marburg (UKGM), Universitaetsklinikum Marburg, Marburg, Germany (CW), Institute of Pathology, Agaplesion Diakonieklinikum Rotenburg Wümme gGmbH, Germany (IB).
本案例报告详细介绍了一名16岁的男孩,患有严重急性呼吸困扰综合征 (ARDS),由电子烟或电子烟使用相关的肺损伤 (EVALI) 引起. 血酶对他的康复至关重要,突出了它在治疗严重EVALI病例中的潜力.
科学领域:
- 肺部病理学 肺部病理学
- 毒理学 毒理学 毒理学
- 关键护理医学 关键护理医学
背景情况:
- 电子烟或电子烟使用相关的肺损伤 (EVALI) 在2019年出现,主要影响患有急性呼吸困扰综合征 (ARDS) 的年轻人.
- EVALI诊断可能具有挑战性,特别是与SARS-CoV-2感染和儿科炎症多系统综合征 (PIMS) 等同时发生的疾病.


